Atossa Therapeutics, Inc.ATOSNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+5.9%
5Y CAGR+17.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+5.9%/yr
vs +24.7%/yr prior
5Y CAGR
+17.6%/yr
Recent deceleration
Acceleration
-18.9pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.2x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $32.85M | +18.9% |
| 2024 | $27.62M | -12.0% |
| 2023 | $31.38M | +13.3% |
| 2022 | $27.69M | +34.9% |
| 2021 | $20.52M | +40.5% |
| 2020 | $14.61M | -15.4% |
| 2019 | $17.27M | +51.0% |
| 2018 | $11.43M | +62.0% |
| 2017 | $7.06M | +1.6% |
| 2016 | $6.95M | - |